InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,749.46
(
0.94%
)
US TECH 100
19,543.80
(
1.35%
)
Dow Jones
42,083.52
(
0.31%
)
Brent Oil
77.41
(
-4.36%
)
Bitcoin
62,071.44
(
-0.24%
)
Post# of 253295
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: genisi post# 122398

Monday, 06/27/2011 7:24:22 AM

Monday, June 27, 2011 7:24:22 AM

Post# of 253295

Ponezumab (PF-04360365) and solanezumab (LY-206430) both were shown to raise CSF Abeta levels (including Abeta forms that are thought to only be present in brain plaques), which may be evidence of biological activity i.e. Abeta clearance from the brain.

Are you aware of any small-cap biotechs with drugs similar to ponezumab and/or solanezumab that have the potential benefit of raising CSF Abeta levels (either in the clinic or pre-clinical)? T.i.a.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up